Abstract
Background Antibodies against phosphorylcholine (anti-PC) are reported to protect against infection. However, the association between cord serum anti-PC and bacterial infection in neonates is yet to be investigated. This study aimed to investigate these associations among both singletons and twins.
Methods A total of 1007 neonates (329 singletons and 678 twins) within the hospital-based Shenzhen Baoan Birth & Twin cohort were included in this study. Levels of IgM anti-PC, IgG anti-PC, as well as IgM, IgG, and IgA in cord serum were measured by enzyme-linked immunosorbent assay. Diagnoses of bacterial infections were identified within 0-27 days after birth. Multivariable logistic regression with propensity score adjustment was performed to assess the associations between levels of antibodies and neonatal bacterial infections.
Results The mean (standard deviation) levels of IgM and IgG anti-PC were 46.68 (14.15) ng/ml and 73.68 (30.44) ng/ml, respectively. Neonatal bacterial infections were diagnosed in 24 singletons (7.29%) and 48 twins (7.08%). A higher level of IgM anti-PC was associated with a lower risk of neonatal bacterial infections in the analyses of singletons (Odds ratio [OR]: 0.64, 95% confidence interval [CI]: 0.41-0.99) or discordant twin pairs (concerning bacterial infection) (OR: 0.44, 95% CI: 0.20-0.95). Statistically significant association was also shown for IgG among singletons and the first-born twins, but not for IgG anti-PC, IgM, or IgA.
Conclusion A higher cord serum level of IgM anti-PC is associated with a lower risk of bacterial infections in neonates.
Key point A higher level of IgM anti-PC in cord serum is associated with a lower risk of bacterial infection in both singleton and twin neonates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the 100 Talents Plan Foundation of Sun Yat-sen University (R. Chen, Grant No.: 58000-12230022), the Guangdong Basic and Applied Basic Research Fund (R. Chen, Grant No.: 2022A1515110417), the Science, Technology and Innovation Council of Shenzhen [X. Chen, Grant No.: JCYJ20190809152801661], and the National Natural Science Foundation of China (X. Chen, Grant No.: 82001652).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Baoan Women's and Children's Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.